# US 2021/0333288 A1 · Glycan oxonium ion profiling of glycosylated proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0333288 A1
- Document ID: US20210333288A1
- Status: Published application
- Kind: A1
- Application number: 16/326,017
- Filed: 2017-08-17
- Published: 2021-10-28
- Earliest claimed: 2016-08-17
- Assignees: Momenta Pharmaceuticals, Inc.
- Applicants: Momenta Pharmaceuticals, Inc.
- Inventors: James Madsen; Victor Farutin
- Web page: https://patentgrep.com/patent/US20210333288A1

## CPC

- C12P 21/005: {Glycopeptides, glycoproteins}
- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- G01N 33/6854: {Immunoglobulins}
- G01N 2440/38: addition of carbohydrates, e.g. glycosylation, glycation
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods disclosed herein include an improved technique for comparing a glycosylation profile of a first protein (e.g., an innovator protein drug) with a glycosylation profile of a second protein (e.g., a corresponding biogeneric/biosimilar). For example, a method of manufacture can include providing or obtaining a batch of a test glycoprotein drug substance, using mass spectrometry to acquire a test oxonium ion profile from a sample of the test glycoprotein drug substance batch, comparing the test oxonium ion profile to a corresponding target oxonium ion profile of a target glycoprotein drug product, and processing the batch of the test glycoprotein drug substance as a drug product if the difference between the test oxonium ion profile and the corresponding target oxonium ion profile is tolerable, or taking an alternative action if the difference between the test oxonium ion profile and the target oxonium ion profile is not tolerable.

## Claims

### Claim 1

A method of manufacture, comprising:
providing or obtaining a batch of a test glycoprotein drug substance;
using mass spectrometry to acquire a test oxonium ion profile from a sample of the test glycoprotein drug substance batch;
comparing the test oxonium ion profile to a corresponding target oxonium ion profile of a target glycoprotein drug product; and
processing the batch of the test glycoprotein drug substance as a drug product if the difference between the test oxonium ion profile and the corresponding target oxonium ion profile is tolerable; or
taking an alternative action if the difference between the test oxonium ion profile and the target oxonium ion profile is not tolerable.

### Claim 2 (depends on 1)

The method of claim 1, wherein the test glycoprotein drug substance comprises a glycoprotein that has an amino acid sequence that is identical to a glycoprotein of the target glycoprotein drug product.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the test glycoprotein drug substance comprises an Fc fusion protein or an antibody.

### Claim 4

The method of any one of the preceding claims, wherein the target glycoprotein drug product is approved under a primary approval process.

### Claim 5

The method of any one of the preceding claims, wherein the target glycoprotein drug product is approved under a BLA.

### Claim 6

The method of any one of the preceding claims, wherein using mass spectrometry comprises digesting the sample to produce a plurality of glycopeptides and/or glycans.

### Claim 7

The method of any one of the preceding claims, wherein using mass spectrometry comprises performing liquid chromatography-tandem mass spectrometry.

### Claim 8

The method of any one of the preceding claims, wherein using mass spectrometry comprises performing data-independent mass spectrometry.

### Claim 9

The method of any one of the preceding claims, wherein using mass spectrometry comprises performing all ion fragmentation.

### Claim 10

The method of any one of the preceding claims, wherein the test oxonium ion profile comprises one or more MS signals associated with levels of oxonium ion-containing fragments that include the following oxonium ions:
(i) HexNAc internal fragment;
(ii) Hex;
(iii) HexNAc;
(iv) sialic acid;
(v) sialic acid+H2O;
(vi) Hex+HexNAc; or
(vii) combinations thereof.

### Claim 11

The method of any one of the preceding claims, wherein the test oxonium ion profile comprises one or more MS signals associated with levels of oxonium ion-containing fragments that include oxonium ions having the following m/z values as well as any associated isotope peaks:
(i) m/z 138.06 (monoisotopic), 139.06 (+1 isotope), 140.06 (+2 isotope);
(ii) m/z 163.06 (monoisotopic), 164.06 (+1 isotope), 165.06 (+2 isotope);
(iii) m/z 204.09 (monoisotopic), 205.09 (+1 isotope), 206.09 (+2 isotope);
(iv) m/z 274.09 (monoisotopic), 275.10 (+1 isotope), 276.10 (+2 isotope);
(v) m/z 292.10 (monoisotopic), 293.11 (+1 isotope), 294.11 (+2 isotope);
(vi) m/z 366.14 (monoisotopic), 367.14 (+1 isotope), 368.14 (+2 isotope); or
(vii) combinations thereof.

### Claim 12

The method of any one of the preceding claims, further comprising producing a representation of the comparison of the test oxonium ion profile to the target oxonium ion profile.

### Claim 13

The method of any one the preceding claims, further comprising using mass spectrometry to acquire a target oxonium ion profile of the target glycoprotein drug product.

### Claim 14

The method of any one of the preceding claims, wherein the difference between the test oxonium ion profile and the corresponding target oxonium ion profile is tolerable if the difference between a level of at least one oxonium ion-containing fragment derived from the test oxonium ion profile and a level of at least one oxonium ion-containing fragment derived from the corresponding target oxonium ion profile is less than a predetermined value.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1-13, wherein the difference between the test oxonium ion profile and the corresponding target oxonium ion profile is not tolerable if the difference between a level of at least one oxonium ion-containing fragment derived from the test oxonium ion profile and a level of at least one oxonium ion-containing fragment derived from the corresponding target oxonium ion profile is greater than a predetermined value.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1-13, wherein the test oxonium ion profile comprises one or more MS signals that are each associated with a level of an oxonium ion-containing fragment and the target oxonium ion profile comprises one or more MS signals that are each associated with a level of an oxonium ion-containing fragment.

### Claim 17 (depends on 16)

The method of claim 16, wherein the difference between the test oxonium ion profile and the corresponding target oxonium ion profile is tolerable if the difference between 2, 3, 4, 5, or more MS signals of the test oxonium ion profile and 2, 3, 4, 5 or more corresponding MS signals of the target oxonium ion profile is each less than a predetermined value.

### Claim 18 (depends on 16)

The method of claim 16, wherein the difference between the test oxonium ion profile and the corresponding target oxonium ion profile is not tolerable if the difference between 1, 2, 3, 4, 5, or more MS signals of the test oxonium ion profile and 1, 2, 3, 4, 5 or more corresponding MS signals of the target oxonium ion profile is each greater than a predetermined value.

### Claim 19 (depends on 14, 15, 17, 18)

The method of any one of claims 14-15 and 17-18, wherein the predetermined value is equivalent to the variability in oxonium ion profiles determined for three or more distinct batches of the target glycoprotein.

### Claim 20 (depends on 14, 15, 17, 18)

The method of any one of claims 14-15 and 17-18, wherein the predetermined value is 20%, 15%, 10% or 5%.

### Claim 21

The method of any one of the preceding claims, wherein the alternative action comprises disposing of the batch of the test glycoprotein drug substance, classifying for disposal the batch of the test glycoprotein drug substance, labeling the batch of the test glycoprotein drug substance for disposal, reprocessing the batch of the test glycoprotein drug substance or a combination thereof.

### Claim 22

The method of any one of the preceding claims, wherein the processing step comprises:
(i) formulating the batch of the test glycoprotein drug substance;
(ii) combining the batch of the test glycoprotein drug substance with a second component, e.g., an excipient or buffer;
(iii) changing the concentration of the batch of the test glycoprotein drug substance in the drug product;
(iv) lyophilizing the batch of the test glycoprotein drug substance;
(v) combining a first and second aliquot of the batch of the test glycoprotein drug substance to provide a third, larger aliquot;
(vi) dividing the batch of the test glycoprotein drug substance into smaller aliquots;
(vii) disposing the batch of the test glycoprotein drug substance into a container, e.g., a gas or liquid tight container;
(viii) packaging the batch of the test glycoprotein drug substance;
(ix) associating a container comprising the batch of the test glycoprotein drug substance with a label (e.g., labeling);
(x) shipping or moving the batch of the test glycoprotein drug substance to a different location; or
(xi) a combination thereof.
